|52Wk High:||52Wk Low:|
CorMedix Inc. is an emerging commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix's first commercial product in Europe is Neutrolin, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. CorMedix initiated a Phase 3 clinical study in the United States in December 2015. CorMedix enjoys a solid patent portfolio, and expanding product pipeline, and the important benefits of fast-track status as well as a qualified infectious disease product designation. The initial and subsequent products under development will address significant unmet needs in the United States and in the rest of the world.